25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

HBPCF (Helix BioPharma Corp) Stock Analysis
Buy, Hold or Sell?

Let's analyze Helix BioPharma Corp together

I guess you are interested in Helix BioPharma Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Helix BioPharma Corp’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Helix BioPharma Corp’s Price Targets

I'm going to help you getting a better view of Helix BioPharma Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Helix BioPharma Corp

I send you an email if I find something interesting about Helix BioPharma Corp.

1. Quick Overview

1.1. Quick analysis of Helix BioPharma Corp (30 sec.)










1.2. What can you expect buying and holding a share of Helix BioPharma Corp? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.00
Expected worth in 1 year
$0.00
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$0.00
Return On Investment
0.1%

For what price can you sell your share?

Current Price per Share
$0.60
Expected price per share
$0.6 - $0.6
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Helix BioPharma Corp (5 min.)




Live pricePrice per Share (EOD)
$0.60
Intrinsic Value Per Share
$-0.47 - $-0.02
Total Value Per Share
$-0.47 - $-0.02

2.2. Growth of Helix BioPharma Corp (5 min.)




Is Helix BioPharma Corp growing?

Current yearPrevious yearGrowGrow %
How rich?-$13.9k$79.4k-$416.7k-123.6%

How much money is Helix BioPharma Corp making?

Current yearPrevious yearGrowGrow %
Making money-$1.8m-$1m-$767.8k-42.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Helix BioPharma Corp (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#758 / 884

Most Revenue
#846 / 884

Most Profit
#287 / 884

Most Efficient
#366 / 884
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Helix BioPharma Corp?

Welcome investor! Helix BioPharma Corp's management wants to use your money to grow the business. In return you get a share of Helix BioPharma Corp.

First you should know what it really means to hold a share of Helix BioPharma Corp. And how you can make/lose money.

Speculation

The Price per Share of Helix BioPharma Corp is $0.6. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Helix BioPharma Corp.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Helix BioPharma Corp, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.00. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Helix BioPharma Corp.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.01-2.3%-0.01-2.1%-0.01-0.8%-0.01-1.3%-0.01-1.5%-0.01-2.1%
Usd Book Value Change Per Share0.012.2%0.000.0%0.00-0.4%0.000.3%0.00-0.1%0.00-0.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.012.2%0.000.0%0.00-0.4%0.000.3%0.00-0.1%0.00-0.1%
Usd Price Per Share0.45-0.33-0.14-0.21-0.36-10.21-
Price to Earnings Ratio-8.24--6.62--7.79--7.08--11.61--165.87-
Price-to-Total Gains Ratio33.71--60.91--17.91--25.42--25.52--1,064.67-
Price to Book Ratio-2,386.31--771.65--22.37--259.47--150.89--8,339.12-
Price-to-Total Gains Ratio33.71--60.91--17.91--25.42--25.52--1,064.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.6
Number of shares1666
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (1666 shares)0.30-0.55
Gains per Year (1666 shares)1.20-2.19
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101-90-2-12
202-80-4-14
304-70-7-16
405-60-9-18
506-50-11-20
607-40-13-22
708-30-15-24
8010-20-18-26
9011-10-20-28
1001200-22-30

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%1.057.043.01.0%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%8.012.00.040.0%14.026.00.035.0%32.069.00.031.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0101.00.0%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%8.012.00.040.0%14.026.00.035.0%32.069.00.031.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Helix BioPharma Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0130.000+7320%-0.002+117%0.002+665%0.000+102%-0.001+104%
Book Value Per Share--0.000-0.004+1926%0.000-150%-0.001+670%0.001-119%0.006-103%
Current Ratio--0.9870.719+37%1.199-18%1.128-12%1.453-32%1.748-44%
Debt To Asset Ratio--1.0081.920-47%1.167-14%1.381-27%1.368-26%1.279-21%
Debt To Equity Ratio----0%0.696-100%1.160-100%0.873-100%2.297-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--33175070.00034485958.178-4%29200162.798+14%30213087.428+10%50297778.916-34%995870148.395-97%
Eps---0.014-0.013-6%-0.005-63%-0.008-41%-0.009-33%-0.013-7%
Ev To Ebitda Ratio---8.225-6.525-21%-7.867-4%-7.039-14%-9.182+12%-168.968+1954%
Free Cash Flow Per Share---0.009-0.006-35%-0.006-39%-0.006-35%-0.008-13%-0.012+31%
Free Cash Flow To Equity Per Share--0.0170.003+474%-0.002+114%0.001+1353%0.001+1438%0.002+921%
Gross Profit Margin--1.0001.037-4%1.041-4%1.026-3%1.016-2%1.008-1%
Intrinsic Value_10Y_max---0.024----------
Intrinsic Value_10Y_min---0.473----------
Intrinsic Value_1Y_max---0.021----------
Intrinsic Value_1Y_min---0.049----------
Intrinsic Value_3Y_max---0.050----------
Intrinsic Value_3Y_min---0.147----------
Intrinsic Value_5Y_max---0.061----------
Intrinsic Value_5Y_min---0.243----------
Market Cap44493480.000+25%33370110.00035057830.178-5%29296394.798+14%30555634.094+9%50543566.116-34%896467188.756-96%
Net Profit Margin----0%-0%-0%-0%-3.0440%
Operating Margin----0%-0%-0%-0%-3.0330%
Operating Ratio----0%-0%-0%-0%5.295-100%
Pb Ratio-3181.742-33%-2386.306-771.645-68%-22.372-99%-259.468-89%-150.895-94%-8339.123+249%
Pe Ratio-10.991-33%-8.244-6.620-20%-7.794-5%-7.078-14%-11.612+41%-165.867+1912%
Price Per Share0.600+25%0.4500.328+37%0.143+216%0.210+114%0.362+24%10.207-96%
Price To Free Cash Flow Ratio-16.044-33%-12.033-13.386+11%-6.265-48%-8.739-27%-10.665-11%-147.219+1123%
Price To Total Gains Ratio44.947+25%33.710-60.906+281%-17.915+153%-25.417+175%-25.516+176%-1064.668+3258%
Quick Ratio--0.9870.616+60%1.064-7%1.020-3%1.275-23%1.611-39%
Return On Assets---0.613-2.246+266%-1.555+154%-1.405+129%-1.136+85%-1.027+68%
Return On Equity----0%-0.8700%-0.6970%-0.6220%-2.6270%
Total Gains Per Share--0.0130.000+7320%-0.002+117%0.002+665%0.000+102%-0.001+104%
Usd Book Value---13984.000-337272.000+2312%79488.000-118%-101016.000+622%173880.000-108%478326.400-103%
Usd Book Value Change Per Share--0.0130.000+7320%-0.002+117%0.002+665%0.000+102%-0.001+104%
Usd Book Value Per Share--0.000-0.004+1926%0.000-150%-0.001+670%0.001-119%0.006-103%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--33175070.00034485958.178-4%29200162.798+14%30213087.428+10%50297778.916-34%995870148.395-97%
Usd Eps---0.014-0.013-6%-0.005-63%-0.008-41%-0.009-33%-0.013-7%
Usd Free Cash Flow---693312.000-676752.000-2%-1178152.000+70%-982008.000+42%-1193681.600+72%-1382668.000+99%
Usd Free Cash Flow Per Share---0.009-0.006-35%-0.006-39%-0.006-35%-0.008-13%-0.012+31%
Usd Free Cash Flow To Equity Per Share--0.0170.003+474%-0.002+114%0.001+1353%0.001+1438%0.002+921%
Usd Market Cap44493480.000+25%33370110.00035057830.178-5%29296394.798+14%30555634.094+9%50543566.116-34%896467188.756-96%
Usd Price Per Share0.600+25%0.4500.328+37%0.143+216%0.210+114%0.362+24%10.207-96%
Usd Profit---1012000.000-1806880.000+79%-1039048.000+3%-1287325.333+27%-1377681.600+36%-1503132.800+49%
Usd Revenue----0%-0%-0%-0%496.800-100%
Usd Total Gains Per Share--0.0130.000+7320%-0.002+117%0.002+665%0.000+102%-0.001+104%
 EOD+7 -1MRQTTM+18 -13YOY+20 -123Y+23 -95Y+16 -1610Y+17 -17

3.3 Fundamental Score

Let's check the fundamental score of Helix BioPharma Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-10.991
Price to Book Ratio (EOD)Between0-1-3,181.742
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.987
Current Ratio (MRQ)Greater than10.987
Debt to Asset Ratio (MRQ)Less than11.008
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.613
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Helix BioPharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5099.950
Ma 20Greater thanMa 500.600
Ma 50Greater thanMa 1000.593
Ma 100Greater thanMa 2000.522
OpenGreater thanClose0.600
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Helix BioPharma Corp

Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.

Fundamental data was last updated by Penke on 2025-06-18 01:11:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Helix BioPharma Corp earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-304.4%+304.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM--141.4%+141.4%
YOY--186.1%+186.1%
3Y--248.3%+248.3%
5Y--338.6%+338.6%
10Y-304.4%-488.9%+184.5%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Helix BioPharma Corp is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • -61.3% Return on Assets means thatΒ Helix BioPharma Corp generatedΒ $-0.61 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Helix BioPharma Corp:

  • The MRQ is -61.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -224.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-61.3%TTM-224.6%+163.3%
TTM-224.6%YOY-155.5%-69.1%
TTM-224.6%5Y-113.6%-111.0%
5Y-113.6%10Y-102.7%-10.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-61.3%-11.5%-49.8%
TTM-224.6%-11.6%-213.0%
YOY-155.5%-11.4%-144.1%
3Y-140.5%-11.8%-128.7%
5Y-113.6%-12.1%-101.5%
10Y-102.7%-13.8%-88.9%
4.3.1.3. Return on Equity

Shows how efficient Helix BioPharma Corp is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Helix BioPharma Corp generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-87.0%+87.0%
TTM-5Y-62.2%+62.2%
5Y-62.2%10Y-262.7%+200.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.6%+13.6%
TTM--14.9%+14.9%
YOY-87.0%-14.4%-72.6%
3Y-69.7%-17.0%-52.7%
5Y-62.2%-17.9%-44.3%
10Y-262.7%-20.1%-242.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Helix BioPharma Corp.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Helix BioPharma Corp is operatingΒ .

  • Measures how much profit Helix BioPharma Corp makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Helix BioPharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-303.3%+303.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM--250.3%+250.3%
YOY--205.1%+205.1%
3Y--220.2%+220.2%
5Y--342.6%+342.6%
10Y-303.3%-475.5%+172.2%
4.3.2.2. Operating Ratio

Measures how efficient Helix BioPharma Corp is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y5.295-5.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM-2.704-2.704
YOY-3.063-3.063
3Y-3.576-3.576
5Y-4.713-4.713
10Y5.2956.512-1.217
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Helix BioPharma Corp.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Helix BioPharma Corp is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.99Β means the company has $0.99 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.987. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.719. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.987TTM0.719+0.268
TTM0.719YOY1.199-0.480
TTM0.7195Y1.453-0.734
5Y1.45310Y1.748-0.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9873.661-2.674
TTM0.7193.786-3.067
YOY1.1994.121-2.922
3Y1.1284.680-3.552
5Y1.4535.765-4.312
10Y1.7486.150-4.402
4.4.3.2. Quick Ratio

Measures if Helix BioPharma Corp is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.99Β means the company can pay off $0.99 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.987. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.616. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.987TTM0.616+0.371
TTM0.616YOY1.064-0.448
TTM0.6165Y1.275-0.659
5Y1.27510Y1.611-0.336
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9872.826-1.839
TTM0.6163.128-2.512
YOY1.0643.782-2.718
3Y1.0204.304-3.284
5Y1.2755.703-4.428
10Y1.6116.454-4.843
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Helix BioPharma Corp.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Helix BioPharma CorpΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Helix BioPharma Corp to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.01Β means that Helix BioPharma Corp assets areΒ financed with 100.8% credit (debt) and the remaining percentage (100% - 100.8%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Helix BioPharma Corp:

  • The MRQ is 1.008. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.920. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ1.008TTM1.920-0.911
TTM1.920YOY1.167+0.752
TTM1.9205Y1.368+0.552
5Y1.36810Y1.279+0.089
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0080.324+0.684
TTM1.9200.347+1.573
YOY1.1670.327+0.840
3Y1.3810.339+1.042
5Y1.3680.349+1.019
10Y1.2790.382+0.897
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Helix BioPharma Corp is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Helix BioPharma Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.696-0.696
TTM-5Y0.873-0.873
5Y0.87310Y2.297-1.425
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.383-0.383
TTM-0.436-0.436
YOY0.6960.410+0.286
3Y1.1600.446+0.714
5Y0.8730.460+0.413
10Y2.2970.509+1.788
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Helix BioPharma Corp generates.

  • Above 15 is considered overpriced butΒ always compareΒ Helix BioPharma Corp to theΒ Biotechnology industry mean.
  • A PE ratio of -8.24 means the investor is paying $-8.24Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Helix BioPharma Corp:

  • The EOD is -10.991. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.244. Based on the earnings, the company is expensive. -2
  • The TTM is -6.620. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.991MRQ-8.244-2.748
MRQ-8.244TTM-6.620-1.623
TTM-6.620YOY-7.794+1.173
TTM-6.6205Y-11.612+4.992
5Y-11.61210Y-165.867+154.255
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.991-2.197-8.794
MRQ-8.244-2.027-6.217
TTM-6.620-2.527-4.093
YOY-7.794-3.733-4.061
3Y-7.078-3.717-3.361
5Y-11.612-6.036-5.576
10Y-165.867-6.649-159.218
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Helix BioPharma Corp:

  • The EOD is -16.044. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.033. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -13.386. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.044MRQ-12.033-4.011
MRQ-12.033TTM-13.386+1.353
TTM-13.386YOY-6.265-7.121
TTM-13.3865Y-10.665-2.721
5Y-10.66510Y-147.219+136.554
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.044-3.007-13.037
MRQ-12.033-2.704-9.329
TTM-13.386-3.627-9.759
YOY-6.265-4.334-1.931
3Y-8.739-5.070-3.669
5Y-10.665-8.532-2.133
10Y-147.219-9.305-137.914
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Helix BioPharma Corp is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -2,386.31 means the investor is paying $-2,386.31Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Helix BioPharma Corp:

  • The EOD is -3,181.742. Based on the equity, the company is expensive. -2
  • The MRQ is -2,386.306. Based on the equity, the company is expensive. -2
  • The TTM is -771.645. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3,181.742MRQ-2,386.306-795.435
MRQ-2,386.306TTM-771.645-1,614.661
TTM-771.645YOY-22.372-749.273
TTM-771.6455Y-150.895-620.751
5Y-150.89510Y-8,339.123+8,188.228
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3,181.7421.921-3,183.663
MRQ-2,386.3061.843-2,388.149
TTM-771.6452.113-773.758
YOY-22.3722.467-24.839
3Y-259.4682.541-262.009
5Y-150.8953.666-154.561
10Y-8,339.1234.311-8,343.434
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-01-31. Currency in CAD. All numbers in thousands.

Summary
Total Assets2,242
Total Liabilities2,261
Total Stockholder Equity-19
 As reported
Total Liabilities 2,261
Total Stockholder Equity+ -19
Total Assets = 2,242

Assets

Total Assets2,242
Total Current Assets2,232
Long-term Assets10
Total Current Assets
Cash And Cash Equivalents 1,996
Net Receivables 236
Total Current Assets  (as reported)2,232
Total Current Assets  (calculated)2,232
+/-0
Long-term Assets
Property Plant Equipment 10
Long-term Assets  (as reported)10
Long-term Assets  (calculated)10
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,261
Long-term Liabilities0
Total Stockholder Equity-19
Total Current Liabilities
Accounts payable 1,440
Other Current Liabilities 821
Total Current Liabilities  (as reported)2,261
Total Current Liabilities  (calculated)2,261
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock161,257
Retained Earnings -213,382
Other Stockholders Equity 52,106
Total Stockholder Equity (as reported)-19
Total Stockholder Equity (calculated)-19
+/-0
Other
Capital Stock161,257
Cash and Short Term Investments 1,996
Common Stock Shares Outstanding 9,804
Liabilities and Stockholders Equity 2,242
Net Debt -1,996
Net Invested Capital -19
Net Working Capital -29
Property Plant and Equipment Gross 1,242



6.2. Balance Sheets Structured

Currency in CAD. All numbers in thousands.

 Trend2025-01-312024-10-312024-07-312024-04-302024-01-312023-10-312023-07-312023-04-302023-01-312022-10-312022-07-312022-04-302022-01-312021-10-312021-07-312021-04-302021-01-312020-10-312020-07-312020-04-302020-01-312019-10-312019-07-312019-04-302019-01-312018-10-312018-07-312018-04-302018-01-312017-10-312017-07-312017-04-302017-01-312016-10-312016-07-312016-04-302016-01-312015-10-312015-07-312015-04-302015-01-312014-10-312014-07-312014-04-302014-01-312013-10-312013-07-312013-04-302013-01-312012-10-312012-07-312012-04-302012-01-312011-10-312011-07-312011-04-302011-01-312010-10-312010-07-312010-04-302010-01-312009-10-312009-07-312009-04-302009-01-312008-10-312008-07-312008-04-302008-01-312007-10-312007-07-312007-04-302007-01-312006-10-312006-07-312006-04-302006-01-312005-10-312005-07-312005-04-302005-01-312004-10-312004-07-312004-04-302004-01-312003-10-312003-07-312003-04-302003-01-312002-10-312002-07-312002-04-302002-01-312001-10-312001-07-312001-04-302001-01-312000-10-312000-07-312000-04-302000-01-31
> Total Assets 
5,673
11,132
9,875
12,253
11,424
12,605
11,930
10,779
10,233
9,596
9,047
8,781
12,426
12,538
11,491
11,582
11,418
10,154
9,388
13,338
12,150
11,030
9,448
11,768
15,291
14,752
13,668
18,204
16,041
15,290
13,373
13,359
25,869
24,138
21,169
24,264
21,185
19,211
17,921
26,236
22,712
19,991
17,703
23,984
22,854
26,979
24,371
21,709
16,021
10,002
7,616
5,828
10,265
8,151
5,868
3,690
5,518
3,663
7,853
5,593
3,561
9,997
7,796
5,692
3,271
5,583
4,468
3,248
2,493
2,269
2,187
4,095
2,653
1,714
1,147
1,780
1,195
1,599
940
2,435
2,739
5,561
4,906
4,578
5,001
3,023
4,065
2,313
944
2,335
3,730
4,801
3,197
1,586
1,029
1,895
344
1,145
1,489
414
2,242
2,2424141,4891,1453441,8951,0291,5863,1974,8013,7302,3359442,3134,0653,0235,0014,5784,9065,5612,7392,4359401,5991,1951,7801,1471,7142,6534,0952,1872,2692,4933,2484,4685,5833,2715,6927,7969,9973,5615,5937,8533,6635,5183,6905,8688,15110,2655,8287,61610,00216,02121,70924,37126,97922,85423,98417,70319,99122,71226,23617,92119,21121,18524,26421,16924,13825,86913,35913,37315,29016,04118,20413,66814,75215,29111,7689,44811,03012,15013,3389,38810,15411,41811,58211,49112,53812,4268,7819,0479,59610,23310,77911,93012,60511,42412,2539,87511,1325,673
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21,680
19,175
13,660
8,191
6,123
4,425
8,964
6,945
5,191
3,067
4,942
3,138
7,405
5,174
3,175
9,642
7,467
5,371
2,984
5,331
4,233
2,936
2,065
1,774
1,700
3,640
2,229
1,306
773
1,434
883
1,316
687
2,199
2,524
5,453
4,660
4,408
4,874
2,936
4,018
2,269
902
2,297
3,695
4,762
3,158
1,551
996
1,854
306
1,111
1,456
404
2,232
2,2324041,4561,1113061,8549961,5513,1584,7623,6952,2979022,2694,0182,9364,8744,4084,6605,4532,5242,1996871,3168831,4347731,3062,2293,6401,7001,7742,0652,9364,2335,3312,9845,3717,4679,6423,1755,1747,4053,1384,9423,0675,1916,9458,9644,4256,1238,19113,66019,17521,6800000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,275
12,630
11,691
10,661
10,147
23,175
21,122
0
22,195
19,021
16,414
13,445
21,837
18,809
15,705
12,827
19,218
18,552
22,948
19,044
17,654
11,919
5,867
4,862
3,313
8,478
6,674
4,493
2,482
4,386
2,832
6,980
4,814
2,723
9,151
6,792
5,008
2,523
4,929
3,654
2,397
1,423
1,323
897
3,175
1,641
770
366
871
306
938
206
1,650
2,094
4,989
4,235
1,428
4,098
2,266
3,565
1,873
471
1,882
3,252
4,397
2,824
1,330
808
1,641
120
710
1,081
228
1,996
1,9962281,0817101201,6418081,3302,8244,3973,2521,8824711,8733,5652,2664,0981,4284,2354,9892,0941,6502069383068713667701,6413,1758971,3231,4232,3973,6544,9292,5235,0086,7929,1512,7234,8146,9802,8324,3862,4824,4936,6748,4783,3134,8625,86711,91917,65419,04422,94818,55219,21812,82715,70518,80921,83713,44516,41419,02122,195021,12223,17510,14710,66111,69112,63014,275000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,631
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000000000002,631000000000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,906
955
950
1,738
733
666
271
117
559
474
348
183
343
328
271
266
491
278
248
242
489
485
477
332
630
409
417
362
315
241
246
158
290
199
172
196
180
166
390
392
353
309
319
349
280
149
105
114
62
69
64
88
54
176
236
23617654886469621141051492803493193093533923901661801961721992901582462413153624174096303324774854892422482784912662713283431833484745591172716667331,7389509551,9060000000000000000000000000000000000000000000000
       Other Current Assets 
111
84
118
0
172
132
97
87
91
129
134
180
291
148
170
182
139
150
136
135
188
175
234
163
235
113
141
113
44
99
175
269
77
397
436
183
132
404
973
642
142
470
389
243
210
268
202
141
286
130
107
141
215
154
139
111
208
123
82
32
181
225
184
85
213
160
90
54
165
119
173
56
171
174
92
322
331
220
191
350
258
464
425
2,980
386
278
100
87
112
66
164
365
229
107
126
144
122
313
321
0
0
0032131312214412610722936516466112871002783862,98042546425835019122033132292174171561731191655490160213851842251813282123208111139154215141107130286141202268210243389470142642973404132183436397772691759944113141113235163234175188135136150139182170148291180134129918797132172011884111
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,691
2,534
2,361
1,811
1,493
1,403
1,301
1,206
677
623
576
525
448
419
386
355
329
321
287
252
235
312
428
495
487
455
424
408
374
346
312
283
253
236
215
108
246
170
127
87
47
44
41
37
35
39
39
36
33
41
38
34
33
10
10
101033343841333639393537414447871271702461082152362532833123463744084244554874954283122352522873213293553864194485255766236771,2061,3011,4031,4931,8112,3612,5342,6910000000000000000000000000000000000000000000000
       Property Plant Equipment 
268
302
460
0
946
999
867
814
770
731
695
601
586
883
885
1,061
1,082
1,017
1,009
1,165
1,107
1,159
1,172
1,136
1,145
1,152
1,204
1,159
1,053
1,065
1,067
1,190
1,065
1,042
1,125
927
884
1,213
1,678
1,814
1,966
2,044
1,942
1,859
1,853
1,878
2,031
1,874
1,696
1,546
1,049
959
857
762
677
623
576
525
448
419
386
355
329
321
287
252
235
312
428
495
487
455
424
408
374
346
312
283
253
236
215
108
246
170
127
87
47
44
41
37
35
38
39
36
33
41
38
34
33
10
10
101033343841333639383537414447871271702461082152362532833123463744084244554874954283122352522873213293553864194485255766236777628579591,0491,5461,6961,8742,0311,8781,8531,8591,9422,0441,9661,8141,6781,2138849271,1251,0421,0651,1901,0671,0651,0531,1591,2041,1521,1451,1361,1721,1591,1071,1651,0091,0171,0821,0618858835866016957317708148679999460460302268
       Intangible Assets 
0
0
0
0
0
0
0
0
210
177
114
107
3,851
4,084
3,649
3,651
3,373
3,068
2,914
2,920
2,629
2,352
1,824
1,616
1,488
1,488
1,429
1,405
1,308
1,351
118
126
116
112
107
88
84
85
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000008584881071121161261181,3511,3081,4051,4291,4881,4881,6161,8242,3522,6292,9202,9143,0683,3733,6513,6494,0843,85110711417721000000000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
660
660
0
265
444
444
444
444
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0000000001100000000000000000000000000000000000044444444444426506606600000000000000000000000000000000000000000000000
> Total Liabilities 
1,593
1,179
926
1,440
651
502
718
565
670
634
704
625
521
637
520
926
791
790
969
994
1,196
1,131
947
1,110
905
1,223
1,403
1,250
1,467
1,197
1,442
1,424
1,612
1,154
1,118
1,336
1,742
2,227
2,093
2,729
1,737
1,838
2,300
1,987
2,423
1,935
2,258
2,372
5,276
1,886
1,392
1,585
1,277
1,319
948
879
514
650
1,042
803
1,174
1,125
969
1,368
1,004
1,446
1,304
2,341
2,676
3,768
2,204
1,966
2,492
3,221
2,674
3,431
2,881
3,519
4,221
1,769
1,651
1,627
1,925
1,982
1,235
1,713
5,458
5,043
5,036
4,259
3,411
5,666
973
673
1,873
1,273
603
1,505
1,579
1,778
2,261
2,2611,7781,5791,5056031,2731,8736739735,6663,4114,2595,0365,0435,4581,7131,2351,9821,9251,6271,6511,7694,2213,5192,8813,4312,6743,2212,4921,9662,2043,7682,6762,3411,3041,4461,0041,3689691,1251,1748031,0426505148799481,3191,2771,5851,3921,8865,2762,3722,2581,9352,4231,9872,3001,8381,7372,7292,0932,2271,7421,3361,1181,1541,6121,4241,4421,1971,4671,2501,4031,2239051,1109471,1311,1969949697907919265206375216257046346705657185026511,4409261,1791,593
   > Total Current Liabilities 
1,268
865
763
659
536
405
616
474
586
555
632
559
461
580
469
880
752
758
941
972
1,178
1,118
932
1,098
902
1,217
1,403
1,250
1,467
1,197
1,442
1,424
1,612
1,154
1,118
1,336
1,742
2,227
2,002
2,646
1,657
1,760
2,229
1,922
2,363
1,878
2,210
2,331
5,241
1,857
1,369
1,568
1,267
1,315
948
879
514
650
1,042
803
1,174
1,125
969
1,368
1,004
1,446
1,304
2,341
2,677
3,768
2,204
1,966
2,492
3,221
2,674
3,431
2,881
3,519
4,221
1,769
1,651
1,627
1,925
1,982
1,235
1,713
3,874
3,762
4,012
3,312
3,411
5,666
973
674
1,874
1,273
603
1,505
1,579
1,778
2,261
2,2611,7781,5791,5056031,2731,8746749735,6663,4113,3124,0123,7623,8741,7131,2351,9821,9251,6271,6511,7694,2213,5192,8813,4312,6743,2212,4921,9662,2043,7682,6772,3411,3041,4461,0041,3689691,1251,1748031,0426505148799481,3151,2671,5681,3691,8575,2412,3312,2101,8782,3631,9222,2291,7601,6572,6462,0022,2271,7421,3361,1181,1541,6121,4241,4421,1971,4671,2501,4031,2179021,0989321,1181,1789729417587528804695804615596325555864746164055366597638651,268
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
159
99
67
34
2,028
2,037
1,940
1,935
2,468
0
0
0
0
0
0
0
0
0
0
00000000002,4681,9351,9402,0372,0283467991590000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,028
2,037
1,940
1,935
2,468
0
0
0
0
0
0
0
0
0
0
00000000002,4681,9351,9402,0372,02800000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
1,237
835
739
0
509
369
591
449
561
531
609
534
436
555
443
853
727
736
922
951
1,029
989
875
1,060
855
1,200
1,389
1,242
1,464
1,197
529
779
920
493
584
802
1,410
1,969
1,205
1,840
1,263
1,055
1,402
1,540
1,547
940
1,085
1,299
844
1,140
650
744
652
799
304
554
218
246
566
248
514
502
262
770
389
816
715
1,418
1,739
2,123
1,438
1,298
1,752
2,646
1,992
2,968
2,378
2,801
3,040
1,510
1,094
1,090
1,416
1,685
841
1,265
1,466
1,416
1,579
927
599
660
707
391
493
984
335
1,090
855
988
1,440
1,4409888551,0903359844933917076605999271,5791,4161,4661,2658411,6851,4161,0901,0941,5103,0402,8012,3782,9681,9922,6461,7521,2981,4382,1231,7391,4187158163897702625025142485662462185543047996527446501,1408441,2991,0859401,5471,5401,4021,0551,2631,8401,2051,9691,4108025844939207795291,1971,4641,2421,3891,2008551,0608759891,02995192273672785344355543653460953156144959136950907398351,237
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
129
109
41
21
24
0
0
0
0
0
913
645
692
660
533
534
332
258
797
805
395
705
827
382
470
567
829
734
4,397
717
719
824
615
516
644
325
296
404
476
555
660
623
707
598
615
630
589
923
938
1,645
722
585
696
534
644
433
446
667
1,057
196
473
537
350
198
327
414
380
309
493
450
344
5,006
266
283
1,381
289
268
415
724
790
821
8217907244152682891,3812832665,0063444504933093804143271983505374731961,0576674464336445346965857221,6459389235896306155987076236605554764042963256445166158247197174,3977348295674703828277053958057972583325345336606926459130000024214110912900000000000000000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
48
41
35
29
23
17
10
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,584
1,281
1,024
947
0
0
0
-1
-1
0
0
0
0
0
0
000000-1-10009471,0241,2811,58400000000000000000-1000000000000004101723293541480000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
91
83
80
78
70
65
60
57
50
41
35
29
23
17
10
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
0
0
0
0
0000000-1000000000000000000000000000000000000000410172329354150576065707880839100000000000000000000000000000000000000
> Total Stockholder Equity
3,937
9,813
8,814
10,813
10,189
11,622
10,801
9,866
9,242
8,685
8,113
7,967
11,904
11,901
10,971
10,656
10,628
9,364
8,419
12,344
10,954
9,899
8,501
10,658
14,386
13,529
12,265
16,954
14,575
14,093
11,931
11,936
24,257
22,985
20,051
22,928
19,443
16,984
15,828
23,506
20,975
18,153
15,404
21,997
20,431
25,044
22,113
19,337
10,745
8,116
6,224
4,243
8,988
6,832
4,920
2,811
5,004
3,013
6,811
4,790
2,387
8,872
6,827
4,324
2,267
4,137
3,164
907
-183
-1,499
-17
2,129
161
-1,507
-1,527
-1,651
-1,686
-1,920
-3,281
45
115
4,788
2,394
2,596
3,766
1,310
-1,393
-2,730
-4,092
-1,924
319
-865
2,224
913
-844
622
-259
-360
-90
-1,364
-19
-19-1,364-90-360-259622-8449132,224-865319-1,924-4,092-2,730-1,3931,3103,7662,5962,3944,78811545-3,281-1,920-1,686-1,651-1,527-1,5071612,129-17-1,499-1839073,1644,1372,2674,3246,8278,8722,3874,7906,8113,0135,0042,8114,9206,8328,9884,2436,2248,11610,74519,33722,11325,04420,43121,99715,40418,15320,97523,50615,82816,98419,44322,92820,05122,98524,25711,93611,93114,09314,57516,95412,26513,52914,38610,6588,5019,89910,95412,3448,4199,36410,62810,65610,97111,90111,9047,9678,1138,6859,2429,86610,80111,62210,18910,8138,8149,8133,937
   Retained Earnings -213,382-212,007-210,671-205,393-203,563-202,661-201,407-199,254-197,908-196,723-195,117-193,731-192,386-190,367-188,554-185,784-183,230-180,738-180,516-178,427-175,938-173,707-171,531-169,363-167,292-165,384-164,005-162,395-160,248-158-155,380-154,140-151,226-148,608-145,321-142,717-140,474-138,248-135,656-133,537-131,716-129,051-126,926-125,122-123,013-120,381-118,244-116,331-114,107-118,776-116,699-114,8440-102,520-98,6110000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
12
13
13
14
15
17
12
11
12
12
11
11
11
11
11
10
11
12
-157,683
13
14
14
14
14
15
15
17
18
20
20
19
20
20,103
19,634
19,699
19,944
17,898
10,335
9,379
7,905
6,312
4,357
3,719
2,485
2,000
0
0
0
0002,0002,4853,7194,3576,3127,9059,37910,33517,89819,94419,69919,63420,10320192020181715151414141413-157,683121110111111111112121112171514131312130000000000000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000



6.3. Balance Sheets

Currency in CAD. All numbers in thousands.




6.4. Cash Flows

Currency in CAD. All numbers in thousands.




6.5. Income Statements

Currency in CAD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-07-31. Currency in CAD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-9,239
Operating Income-9,239-9,239
 
Operating Expense (+$)
Research Development5,977
Selling General Administrative2,575
Selling And Marketing Expenses-
Operating Expense9,2398,552
 
Net Interest Income (+$)
Interest Income31
Interest Expense-7
Other Finance Cost-0
Net Interest Income24
 
Pretax Income (+$)
Operating Income-9,239
Net Interest Income24
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-9,264-9,190
EBIT - interestExpense = -7
-9,264
-9,257
Interest Expense7
Earnings Before Interest and Taxes (EBIT)--9,257
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-9,264
Tax Provision--
Net Income From Continuing Ops-9,264-9,264
Net Income-9,264
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-49-24
 

Technical Analysis of Helix BioPharma Corp
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Helix BioPharma Corp. The general trend of Helix BioPharma Corp is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Helix BioPharma Corp's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Helix BioPharma Corp Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Helix BioPharma Corp.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.6 < 0.6 < 0.6.

The bearish price targets are: 0.6 > 0.6 > 0.6.

Know someone who trades $HBPCF? Share this with them.πŸ‘‡

Helix BioPharma Corp Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Helix BioPharma Corp. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Helix BioPharma Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Helix BioPharma Corp. The current macd is 0.00404731.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Helix BioPharma Corp price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Helix BioPharma Corp. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Helix BioPharma Corp price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Helix BioPharma Corp Daily Moving Average Convergence/Divergence (MACD) ChartHelix BioPharma Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Helix BioPharma Corp. The current adx is 99.19.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Helix BioPharma Corp shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Helix BioPharma Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Helix BioPharma Corp. The current sar is 0.56787988.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Helix BioPharma Corp Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Helix BioPharma Corp. The current rsi is 99.95. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -1/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
Helix BioPharma Corp Daily Relative Strength Index (RSI) ChartHelix BioPharma Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Helix BioPharma Corp. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Helix BioPharma Corp price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Helix BioPharma Corp Daily Stochastic Oscillator ChartHelix BioPharma Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Helix BioPharma Corp. The current cci is 66.67.

Helix BioPharma Corp Daily Commodity Channel Index (CCI) ChartHelix BioPharma Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Helix BioPharma Corp. The current cmo is 100.00.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Helix BioPharma Corp Daily Chande Momentum Oscillator (CMO) ChartHelix BioPharma Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Helix BioPharma Corp. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Helix BioPharma Corp Daily Williams %R ChartHelix BioPharma Corp Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Helix BioPharma Corp.

Helix BioPharma Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Helix BioPharma Corp. The current atr is 0.00036273.

Helix BioPharma Corp Daily Average True Range (ATR) ChartHelix BioPharma Corp Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Helix BioPharma Corp. The current obv is 2,600.

Helix BioPharma Corp Daily On-Balance Volume (OBV) ChartHelix BioPharma Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Helix BioPharma Corp. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Helix BioPharma Corp Daily Money Flow Index (MFI) ChartHelix BioPharma Corp Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Helix BioPharma Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-05-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Helix BioPharma Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Helix BioPharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5099.950
Ma 20Greater thanMa 500.600
Ma 50Greater thanMa 1000.593
Ma 100Greater thanMa 2000.522
OpenGreater thanClose0.600
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Helix BioPharma Corp with someone you think should read this too:
  • Are you bullish or bearish on Helix BioPharma Corp? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Helix BioPharma Corp? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Helix BioPharma Corp

I send you an email if I find something interesting about Helix BioPharma Corp.


Comments

How you think about this?

Leave a comment

Stay informed about Helix BioPharma Corp.

Receive notifications about Helix BioPharma Corp in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.